William Blair analyst Matt Phipps has reiterated their bullish stance on AUTL stock, giving a Buy rating today.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Matt Phipps has given his Buy rating due to a combination of factors, including steady commercial progress for Aucatzyl and clear line of sight to improved profitability. Despite Autolus’s shares falling materially year-to-date on conservative 2026 guidance and uncertainty around gross margin timing, he views 2026 as a transition year focused on commercial execution, patient growth, and manufacturing optimization to move into positive gross margins.
Phipps also sees meaningful long-term upside from expanding Aucatzyl into indications such as pediatric ALL and lupus nephritis, which could lift the therapy into blockbuster territory as data emerge over the next 12–18 months. He believes Aucatzyl’s differentiated safety and efficacy profile, reinforced by encouraging real‑world experience and increasing U.S. center activation, should drive further market share gains, supporting his continued Outperform (Buy) stance on Autolus.
In another report released today, Needham also maintained a Buy rating on the stock with a $10.00 price target.